Results for "psoriasis"

...cravacitinib can alleviate inflammatory processes. Deucravacitinib is approved for the treatment of psoriasis.Tyrosine kinase 2 plays both a structural and catalytic role in the signaling of numerous interleuk...

...ts in a strong anti-inflammatory effect. Indication Moderate and severe, therapy-resistant forms of psoriasis vulgaris, dimethyl fumarate also approved in multiple sclerosis. Limited indication Hematological d...

...ammatory skin diseases that are accompanied by pustule formation. For example, generalized pustular psoriasis (GPP/Zumbusch type) (Farooq M et al. 2013).Other IL36RN-associated diseases are classified as forms...

...ammatory and selective immunosuppressive activity. Risankizumab is used for the treatment of plaque psoriasis.The effects are based on the binding and inactivation of the cytokine interleukin-23 (IL-23). The r...

...or the IL-36 receptor antagonist, are more common in patients diagnosed with both AGEP and pustular psoriasis than in unaffected individuals (Sidoroff A et al. 2007; Meier-Schiesser B et al. 2019; Navarini AA...

...se III studies (AMAGINE-2 and AMAGINE-3) in more than 1,800 patients with moderate to severe plaque psoriasis showed that 36.7% of patients in the 210 mg brodalumab group, 18.5% in a group with the IL-12/-23 a...

...s if their response to previous disease-modifying, anti-rheumatic drug therapy has been inadequate. Psoriasis vulgaris (moderate to severe plaque-type psoriasis in adults who have not responded to other system...

...apeutic is of interest; a large number of publications are available on this topic. General therapy Psoriasis, spondyloarthritis (Spa) with axial as well as peripheral arthritis, ankylosing spondylitis, psoria...

...M. Behçet, dermatomyositis, sarcoidosis, T-cell lymphomas, pemphigus vulgaris, bullous pemphigoid, psoriasis vulgaris, atopic eczema (most severe forms), lichen planus mucosae (topical application also possib...

...nd are all inherited in an autosomal dominant manner, leading to a loss of melanocytes in the skin. Psoriasis: The integrity of the epidermal melanin unit is also disrupted in psoriasis (Nickoloff BJ 2004). It...

...s or candida infections.Exfoliatio areagta linguae occurs more frequently in patients with pustular psoriasis(Psoriasis pustulosa - Dreyer LN et al. 2012). In this context, the detection of IL36RN gene mutatio...

...s study results in other models of inflammation, such as arthritis, inflammatory bowel disease, and psoriasis confirmed the hypothesis of dual use of the IL-12p40 subunit by interleukins-12 and -23.Interleukin...

...antly influences inflammatory processes is IL-17, which plays a central role in the pathogenesis of psoriasis, psoriatic arthritis and rheumatoid arthritis. As antipsoriatic and/or antirheumatic drugs there ar...

...uppressive and anti-inflammatory effects and is used for the treatment of moderate to severe plaque psoriasis. Spectrum of action Ixekinumab binds with high affinity to interleukin-17A (IL-17A) and inhibits in...

...ammatory and selective immunosuppressive effects. Tildrakizumab is used for the treatment of plaque psoriasis. The effects are based on the binding and inactivation of the cytokine interleukin-23 (IL-23). Phar...

...also be used as monotherapy if MTX is not tolerated.In the meantime, there is also an approval for psoriasis as a first-line therapy.Adalimumab can also be used in children with severe plaque psoriasis who ha...

...ments on cytotoxic cells, especially NK cells. Indication For moderately severe and severe forms of psoriasis vulgaris that require systemic treatment ( off-label use, not permitted in Europe!). Pregnancy/nurs...

...esterase-4 inhibitor) developed by Celegene for the indications spondylitis, psoriatic arthritis or psoriasis arthropathica, and moderate to severe psoriasis vulgaris (S3 guideline). A small monocentric study...

...Bimzelx® (bimekizumab) entered the German market on September 15, 2021 for the treatment of plaque psoriasis. Two anti-IL-17A antibodies, ixekizumab and secukinumab, are already approved as of September 2021...

...pro-inflammatory cytokines.Such mutations are also found in about 80% of sporadic cases of pustular psoriasis without additional manifestations of psoriasis vulgaris. In contrast, IL-36RN gene mutations are on...

.... Although the skin lesions show a psoriasiform pattern, there is no etiopathogenic relationship to psoriasis. Classification According to Griffith, a distinction is made between 5 types, to which an HIV-assoc...

PSORS15 Definition PSORS15 (PSORS15 stands for: Psoriasis Susceptibility 15) is a genetic locus associated with psoriasis. The gene is located on chromosome...

...ants have been associated with autoimmune diseases in Europeans. These include:type I diabetes (T1D)psoriasismultiple sclerosis andhyperimmunoglobulin E syndrome (HIES; primary immunodeficiency with elevated I...

...ation of 112 days. Field of application/use Approved for the treatment of moderate to severe plaque psoriasis in adults in whom other basic therapies (e.g. MTX, cyclosporine, fumarates, PUVA) have failed to re...

...n mast cells, neutrophil granulocytes, monocytes and T-cells. LL-37 acts as a Z-cell autoantigen in psoriasis. Dermcidins (DCD) are antimicrobial peptides that are produced in human sweat glands and excreted t...